patented technology to grow and expand adult Stem Cells

Adult stem cell development company commencing clinical trials applicable to estimated $30 billion degenerative disease market place

Free
Message: presenting Dr. Philip Schein "leading international authority in the

one can't help but be concerned about the performance and the actions of this company. The reverse split was a very low blow to retail investors and could have been done at a more opportune time. As Edigokie had pointed out, the fluff PRs actually "put off" potential investors. This is an extremely risky stock - one in one thousand products that go through animal testing actually make it to the shelves. Some of the ones that don't make it even have some big names associated with them.

Share
New Message
Please login to post a reply